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Abstract: This study evaluated the frequency, timing, and character-
istics of flares in a large cohort of Italian patients with biopsy-proven giant
cell arteritis (GCA) and to identify factors at diagnosis able to predict the
occurrence of flares. We evaluated 157 patients with biopsy-proven
transmural GCA diagnosed and followed at the Rheumatology Unit of
Reggio Emilia Hospital (Italy) for whom sufficient information was
available from the time of diagnosis until at least 4 years of follow-up.
Fifty-seven patients (36.5%) experienced1 flares. Fifty-one (46.4%) of
the 110 total flares (88 relapses and 22 recurrences) were experienced
during the first 2 years after diagnosis. The majority of relapses occurred
with doses of prednisone  10 mg/day (82.9%), whereas only 3.4% of
relapses occurred for doses  25 mg/day. Polymyalgia rheumatica
(46.5%) and cranial symptoms (41.9%) were the most frequent manifes-
tations at the time of the first relapse. Cumulative prednisone dose during
the first year and total cumulative prednisone dose were significantly
higher in flaring patients compared with those without flares (7.8 2.4 vs
6.7 2.4 g, P¼ 0.02; 15.5 8.9 vs 10.0 9.2 g, P¼ 0.0001, respect-
ively). The total duration of prednisone treatment was longer in flaring
patients (58 44 vs 30 30 months, P¼ 0.0001).
Patients with disease flares had at diagnosis more frequently systemic
manifestations (P¼ 0.02) and fever  388C (P¼ 0.02), significantly
lower hemoglobin levels (P¼ 0.05), more frequent presence at temporal
artery biopsy (TAB) specimens of giant cells (P¼ 0.04) and intraluminal
acute thrombosis (P¼ 0.007), and more moderate/severe arterial inflam-
mation (P¼ 0.009) compared with those without flares. In the multi-
variate model fever 38 8C (hazard ratio 2.14; 95% confidence interval,
1.06–4.32, P¼ 0.03) and the severity of inflammatory infiltrate (mod-
erate/severe versus mild) (hazard ratio 5.41; 95% confidence interval,Crescentini, MD, e, MD, PhD,
arani, MD
severity of inflammation at TAB appear to predict the development of
disease flares.
(Medicine 95(19):e3524)
Abbreviations: ANOVA = analysis of variance, CI = confidence
interval, CRP = C-reactive protein, ESR = erythrocyte
sedimentation rate, FDG-PET = 18F-FDG positron emission
tomography, GCA = giant cell arteritis, HR = Hazard Ratio, IQR
= interquartile range, LVV = large vessel vasculitis, PMR =
polymyalgia rheumatica, TAB = temporal artery biopsy.
INTRODUCTION
G iant cell arteritis (GCA) is a large- and medium-vesselvasculitis that mainly involves the thoracic aorta and its
branches.1–3 Glucocorticoids (GCs) are the treatment of choice;
adequate doses quickly suppress clinical manifestations of GCA
and mostly prevent ischemic complications. The duration of GC
therapy is variable: in some patients, it can be discontinued
within 1 to 2 years, whereas other patients have a chronic
relapsing course requiring GCs up to several years.4 Clinical
flares have been reported in observational studies as occurring
in 34% to 74.5% of the patients and are strictly related to the
duration of GC treatment.5–14 Flares are more frequent during
the first 2 years of treatment when prednisone dose is reduced to
about 5 to 10 mg/day.5,6 GC-related side effects were commonly
observed in GCA long-term studies and were associated with
the intensity and duration of GC therapy.5,6,8 Identification of
predictors of flares can aid to optimize therapeutic strategies,
minimizing disease flares and reducing the cumulative GC
dose, which is an important risk factor for GC-related side
effects. There are limited observations on predictors of disease
flares in GCA.5,6,9,10,12 Some studies suggested that a strong
systemic inflammatory response at the time of disease diagnosis
may predict the development of disease flares in GCA.5,6,10,12
The aim of this study was to evaluate the frequency, timing,
and characteristics of flares (relapses and recurrences) in a large
cohort of Italian patients with biopsy-proven GCA diagnosed
between 1986 and 2007 and followed up for at least 4 years. In
addition, we evaluated the usefulness of clinical, laboratory
parameters, and comorbidities at diagnosis, as well as temporal
artery histopatological findings as predictors of flares.
PATIENTS AND METHODS
Patients
We reviewed the computerized pathology laboratory’sa record of all temporal artery biopsies
eggio Emilia (Italy) at the Arcispedale
ospital between January 1, 1986 and
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FIGURE 1. Different intensity of transmural inflammation in
Medicine  Volume 95, Number 19, May 2016December 31, 2007. The positive specimens were reviewed by a
pathologist (AC) with expertise in vasculitis.
Patients were diagnosed as having biopsy-proven GCA if
the histological examination of the TAB showed transmural
infiltration of mononuclear cells in the arterial wall with or
without giant cells. TAB procedures in Reggio Emilia have been
described elsewhere.15,16 TAB was routinely performed in all
patients with clinical manifestations of GCA. The length of
TAB was 0.5 cm in all cases. We included only those patients
diagnosed and followed by our Department of Rheumatology
for whom sufficient information was available from the time of
diagnosis until at least 4 years of follow-up. A total of 157
patients satisfied the inclusion criteria and were included in the
study. Although this study is retrospective, all patients were
uniformly evaluated and treated. In this cohort study, we
followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) recommendations for
reporting descriptive observational studies.17 The study was
approved by the local Ethics Committee.
All medical records of these 157 patients were reviewed.
Besides demographic features and comorbid conditions (hyper-
tension, diabetes mellitus, hypercholesterolemia, hypertrigly-
ceridemia, and smoking status),15 the following clinical data at
the time of diagnosis were assessed: headache, abnormal
temporal arteries on physical examination, scalp tenderness,
jaw claudication, carotidodynia, visual manifestations (transient
visual loss including amaurosis fugax, permanent visual loss,
and diplopia), cerebrovascular accidents (stroke and/or transient
ischemic attack), systemic signs/symptoms (at least one of the
following: asthenia, anorexia, weight loss of at least 4 kg, or
fever), fever  388C, polymyalgia rheumatica (PMR) (bilateral
marked aching and stiffness without other apparent cause in at
least 2 of the following regions: neck, shoulder girdle, and hip
girdle), and distal musculoskeletal manifestations.
Laboratory parameters were measured before the onset of
GC therapy and during the follow-up. Erythrocyte sedimen-
tation rate (ESR) was determined using the Westergren method
(since most of our patients were women older than 50 years, the
upper limit of normal considered for ESR was 30 mm/h). C-
reactive protein (CRP) was measured by nephelometry (NA
latex CRP kit; Behringwerke, Marburg, Germany; upper limit of
the normal reference range 0.5 mg/dL). Hemoglobin levels
(anemia if  12 g/dL) and platelet count (elevated if
 450,000 mm3) were also considered.
The pathologist (AC) evaluated the following pathological
findings in temporal artery biopsy specimens: presence of giant
cells, intraluminal acute thrombosis, laminar necrosis, calcifi-
cations, and intimal thickening. He also categorized the degree
of inflammation present in temporal artery specimens as mild,
moderate, and severe (Figure 1).18 All patients with visual loss
at diagnosis or during the follow-up period were examined by an
ophthalmologist (LC). Visual acuity was measured using a
Snellen chart, and visual field was tested with a Goldmann
perimeter.
All patients with GCA were initially treated with pre-
dnisone (40–60 mg/day). Some patients with visual ischemic
manifestations also received intravenous pulses of methyl-
prednisolone (1 g/day for 3 consecutive days) followed by
prednisone 60 mg/day. The initial dose of prednisone was
maintained for the first month, then the dosage was reduced
by 5 mg every 2 to 4 weeks to 20 mg/day. Subsequently, the
Restuccia et alreduction of prednisone dose <20 mg/day was slower and
individualized. Generally, prednisone was reduced by 2.5 mg
every 2 to 4 weeks to 10 mg and then by 1 mg every 1 to 2
2 | www.md-journal.commonths until suspension, provided no relapses occurred. If
relapses occurred, prednisone dose was increased by 10 to
15 mg/day above the previous effective dose, whereas in the
event of recurrences, prednisone dosage 10 to 15 mg/day was
temporal artery biopsy specimens: mild (A), moderate (B) and
severe (C). (A) Hematoxylin-Eosin, 40; (B,C) Hematoxylin-Eosin,
20.reinitiated. If asymptomatic increases in acute-phase reac-
tants were detected, prednisone dose was held until the
next visit.
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In 4 patients, methotrexate (10–15 mg/week) was associ-
ated to GCs as initial treatment.
Disease-related signs/symptoms, ESR and CRP levels, and
GC dosages were recorded at every follow-up visit (scheduled
in most of the patients every 3 months). Cumulative prednisone
dose received after 1 year, as well as the total cumulative
prednisone dose received during the entire study period,
was calculated.
We diagnosed disease flares if all the following criteria
were satisfied: reappearance of signs/symptoms of GCA/
PMR, resolution of signs/symptoms after increasing or
restarting GC, ESR 40 mm/h or CRP 0.5 mg/day, and
exclusion of other causes. Flares occurring during the course
of GC treatment were considered relapses, whereas flares
occurring at least 1 month after GC withdrawal were
considered recurrences.
In case of asymptomatic increases of ESR and/or CRP, the
dosage of GC was maintained stable until the next visit,
other eventual causes for such increases were investigated,
and the dosage of GC was increased only if a clinical flare
was documented.
Long-term remission was defined as permanent discon-
tinuation of prednisone without recurrence of symptoms and
elevation of inflammatory markers for at least 1 year.
Statistical Analysis
Continuous data were described as mean and standard
deviation (meanSD) or median and interquartile range
(IQR), and categorical variables as absolute frequencies and
percentages. Continuous variables were compared by using t
test or Mann-Whitney U test when the distributions were
skewed. Comparison of categorical variables was performed
by using x2 or Fischer exact test. Differences in ESR, CRP
values, and prednisone dose at the time of flare and time from
diagnosis to flare among groups have been tested by means of
analysis of variance.
Cox proportional hazards model was used to estimate
potential predictors (demographic, clinical, laboratory, patho-
logical findings, and comorbidities) of relapse/recurrence
assessed at diagnosis. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were computed for each predictor in the uni-
variate analysis and in the multivariate model using the back-
ward stepwise approach (P¼ 0.10 for removal, P¼ 0.05 for
addition to the model).
Probabilities of no flares (relapses or recurrences) of the
disease were estimated by Kaplan-Meier survival curve, con-
sidering time at first flare as time of failure, and time at the end
of study or death as time at censorship (if the patient had not
suffered any relapse or recurrence of the disease).
Time required to achieve maintenance prednisone dose
<10 mg/day, <5 mg/day, and time to treatment discontinuation
were estimated with the Kaplan-Meier method, and log-rank
test was used to compare time between patients with and
without flares.
Medicine  Volume 95, Number 19, May 2016All test were 2-sided; significance was defined at P< 0.05.
Statistical analysis was performed using SPSS version 22.0
(IBM Statistics, IBM Corp, Armonk, NY).
RESULTS
The study population consisted of 157 patients: 123 (78%)females and 34 (22%) males. Mean (SD) age at diagnosis of
GCA was 74 7.9 years and median follow-up 80 months
(range 49–125 months).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Demographic, clinical, laboratory, pathologic findings,
and comorbidities at diagnosis are shown in Table 1.
Fifty-seven patients (36.5%) had at least 1 flare (relapse
and/or recurrence) during the follow-up, median 1 flare (range
1–7). Twenty-nine patients (18.4%) had at least 2 flares. Forty-
one patients experienced relapses (total number of relapses: 88),
whereas 16 had recurrences (total number of recurrences: 22).
Thirty (27.3%) of the 110 flares were experienced during the
first year after diagnosis. Figure 2 shows Kaplan-Meier estimate
of the probability of flare as a function of months from
diagnosis, whereas Table 2 shows Kaplan-Meier estimates
for the probability of no flare.
The majority of relapses occurred with prednisone dosages
 10 mg/day (73/88: 82.9%), whereas the patients rarely
relapsed for doses of prednisone  20 mg/day (6/88: 6.8%),
and  25 mg/day (3/88: 3.4%). The most frequent clinical
manifestation in the patients who relapsed at a dosage of
prednisone  10 mg/day was PMR (49/73, 67.1%), followed
by cranial symptoms (15/73, 20.5%), systemic symptoms
(11/73, 15.1%), and large vessel vasculitis (LVV) (5/73,
6.8%). PMR was significantly more frequent in patients who
relapsed at a dose of prednisone  10 mg/day compared with
those who relapsed at a prednisone dose>10 mg/day) (67.1% vs
6.7%, P¼ 0.0001), whereas cranial symptoms were statistically
less frequent in patients who relapsed at a prednisone dose
 10 mg/day (20.5% vs 66.7%, P¼ 0.001).
Table 3 shows the distribution of flare types, ESR and CRP
levels at time of flare, prednisone dose at time of flare, time
from diagnosis to flare, and percentage of patients flaring per
year of follow-up. The main clinical manifestation observed
during flares was PMR (57.3), followed by cranial symptoms
(27.3%). Only 1 patient developed a severe ischemic compli-
cation (permanent visual loss because of anterior ischemic optic
neuropathy) 13 months after GCA diagnosis, while she was on
prednisone 12.5 mg/day. Three patients flared with sympto-
matic large vessel involvement: 1 developed a pulsating mass
in the right parasternal area with evidence of inflammatory
ascending aorta aneurysm, 1 a decreased right brachial artery
pulse with evidence of right subclavian artery stenosis, and 1
right lower limb (sural) claudication with evidence of occlusion
of the right superficial femoral artery. In all these 3 patients,
18F-FDG positron emission tomography (FDG-PET) showed
active LVV. The patient with ascending aorta aneurysm had a
second flare 22 months after the first characterized by elevated
inflammatory markers and recurrence of active LVV at FDG-
PET. Five other patients had evidence of LVV at FDG-PET
when they flared. All these 5 patients had persistently elevated
acute phase reactants and 4 associated clinical manifestations (2
headache, 1 PMR, and 1 wrist arthritis). Prednisone was
increased or restarted in all 9 flares with evidence of LVV at
FDG-PET. ESR and CRP were elevated before the flare and
subsequently normalized.
MeanSD of ESR and CRP at time of flare were
54 25 mm/h and 3.8 3 mg/dL, respectively. Mean predni-
sone dose at time of flare was 8.2 8.9 mg/day with a median of
5 mg/day (IQR, 2.5–10 mg/day).
Table 4 shows the main clinical and laboratory data at time
of the first relapse. Polymyalgia rheumatica (46.5%) was the
most common finding followed by cranial symptoms (41.9%).
The patient with permanent visual loss developed this compli-
cation at the first flare. One patient had LVV at FDG-PET
Flares in GCAperformed for persistently elevated ESR and CRP levels.
The mean ESR and CRP values at time of the first relapse
were 53 23 mm/h and 4.4 3.0 mg/dL, the mean prednisone
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TABLE 1. Demographic, Clinical, Laboratory, and Histological Findings and Comorbidities at Diagnosis of 157 Patients With
Temporal Artery Biopsy-Proven GCA and Comparisons of Findings Between Patients With and Without Disease Flares

Characteristic All (n¼ 157) With Flares (/)n¼ 57 Without Flares (n¼ 100) P
Demographic findings
Age, y, meanSD 74 8 73 7 74 7 0.321
Female 123 (78) 46 (80.7) 77 (77) 0.59
Clinical symptoms
Headache 127 (80.9) 47 (82.5) 80 (80) 0.707
Scalp tenderness 60/152 (39.5) 22/55 (40) 38/97 (39.2) 0.920
Abnormalities of temporal artery 107/155 (69.9) 40/57 (70.2) 67/98 (68.4) 0.814
Jaw claudication 83 (52.9) 30 (52.6) 53 (53) 0.965
Carotidynia 16 (10.2) 5 (8.8) 11 (11) 0.657
Visual manifestations 47 (29.9) 18 (31.6) 29 (29) 0.734
Amaurosis fugax 17 (10.8) 7 (12.3) 10 (10) 0.658
Visual loss permanent 28 (17.8) 8 (14) 20 (20) 0.348
Polymyalgia rheumatic 74 (47.1) 28 (49.1) 46 (46) 0.706
Cranial ischemic manifestations

104/151 (68.9) 40/56 (71.4) 64/95 (67.4) 0.663
Systemic manifestations

106 (67.5) 45 (78.9) 61 (61) 0.022
Fever  388C 27 (17.2) 15 (26.3) 12 (12) 0.022
Peripheral arthritis 14/156 (9) 7/57 (12.3) 7/99 (7.1 0.273
Comorbidities
Hypertension 90/139 (64.7) 34/54 (63) 56/85 (65.9) 0.725
Diabetes 8/142 (5.6) 3/57 (5.9) 5/91 (5.5) 0.923
Hypercholesterolemia 19/146 (13.0) 4/54 (7.4) 15/92 (16.3) 0.137
Hypertriglyceridemia 10/144 (6.9) 3/54 (5.6) 7/90 (7.8) 0.743
Heavy smokersy 24/151 (15.9) 10/54 (18.5) 14/97 (14) 0.510
Laboratory
ESR, mm/h, meanSD 87 29 89 31 86 27 0.650
CRP, mg/dL, meanSD 9.1 6.1 9.3 6.0 9.0 6.3 0.827
Hemoglobin, g/dL, meanSD 11.2 1.4 10.9 1.5 11.4 1.3 0.048
Platelet count, 109 cells/L, meanSD 386 113 386 100 386 120 0.991
Pathological findings
Giant cells 119/149 (79.9) 48/54 (88.9) 71/95 (74.7) 0.038
Laminar necrosis 41/149 (27.5) 13/54 (24.2) 28/95 (29.5) 0.478
Calcification 27/152 (17.8) 8/55 (14.5) 19/97 (19.6) 0.434
Intraluminal acute thrombosis 14/149 (9.4) 10/54 (18.5) 4/95 (4.2) 0.007
Grading of inflammation
Mild 28/147 (19) 4/52 (7.7) 24/95 (25.3)
Moderate 49/147 (33.3) 23/52 (44.2) 26/95 (27.4) 0.016
Severe 70/147 (47.6) 25/52 (48.1) 45/95 (47.4)
Intimal hyperplasia
Mild 12/104 (11.5) 2/37 (5.4) 10/67 (14.9)
Moderate 37/104 35.6) 11/37 (29.7) 26/67 (38.8) 0.136
Severe 55/104 (52.9) 24/37 (64.9) 31/67 (46.3)
Therapy
Initial prednisone dose, mg, mean SD 46 16 48 12 45 18 0.276
Prednisone therapy duration, mo 40 38 58 44 30 30 0.0001
Cumulative prednisone dose, 1 year, g 7.145 2.468 7.808 2.391 6.709 2.436 0.016
Total cumulative prednisone dose, g 12.113 9.442 15.545 8.868 10.031 9.210 0.0001
CRP¼C-reactive protein, ESR¼ erythrocyte sedimentation rate, GCA¼ giant cell arteritis.
Values are the number (%), except where otherwise indicated. P values are the comparison between GCA patients with disease flares and those
without disease flares.
Presence of at least one of the following: jaw claudication, amaurosis fugax, permanent visual loss, stroke, or transient ischemic attack.
ght
be
Restuccia et al Medicine  Volume 95, Number 19, May 2016dose was 10.7 11.4 mg/day, with a median of 8.2 mg/day
Presence of at least one of the following: asthenia, anorexia, wei
yPatients who still smoked at the time of GCA diagnosis or who had(IQR, 2.8–12.5 mg. Mean time to first relapse was
14.5 11.8 months with a median of 12 months (IQR,
6.0–18 months).
4 | www.md-journal.comTable 5 compares the main clinical and laboratory data at
loss of at least 4 kg, or fever.
en smoking within the 10 years before the onset of GCA symptoms.time of relapse and at time of recurrence. The frequencies of the
main clinical manifestations were similar, whereas the mean
ESR and CRP values at time of relapse were higher compared
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Main Characteristics and Timing of Flares in 110




Polymyalgia rheumatica 63/110 (57.3)





Systemic manifestationsz 16/110 (14.5)
Acute-phase reactants
ESR, mm/h, meanSD 54 25
CRP, mg/dL, meanSD 3.8 3.0
Prednisone dose, mg/day
MeanSD 8.2 8.9
Median (IQR) 5 (2.5–10)
Time from diagnosis to relapses/recurrences, mo
MeanSD 39.0 37.2
Median (IQR) 27.5 (12–51)







CRP¼C-reactive protein, IQR¼ interquartile range.
Values are the number (%), except where otherwise indicated.
ESR¼ erythrocyte sedimentation rate.
Large vessel involvement: evidence of active large vessel vasculitis
at 18F-FDG positron emission tomography (FDG-PET).
yCranial symptoms: headache, scalp tenderness, jaw claudication,
temporal artery abnormalities, Carotidynia, cranial ischemic compli-
cations.
zPresence of at least one of the following: asthenia, anorexia, weight
Medicine  Volume 95, Number 19, May 2016 Flares in GCAwith those observed at time of recurrence (56 27 vs
49 17 mm/h, and 4.0 3.0 vs 2.7 2.9 mg/dL, respectively),
although the differences were not statistically significant.
Time from diagnosis to flare was significantly higher in
recurrences compared with relapses (66.8 44.1 vs 32.1 32.0
months, P¼ 0.002) because relapses occurred prevalently in the
first year of follow-up (33% vs 4.5%, P¼ 0.006) and recur-
rences after 5 years of follow-up (45.5% vs 15.9%, P¼ 0.007).
Table 1 shows the initial prednisone dose, the therapy
duration, and 1st year and total cumulative prednisone doses in
patients with and without flares. The initial prednisone dosage
FIGURE 2. Kaplan-Meier estimate of the probability of flare
(relapse or recurrence) over time.was not different in patients with and without flares (48 12 vs
45 18 mg/day), whereas the therapy duration (58 44 vs
30 30 months, P¼ 0.0001), the cumulative dose at 1 year
TABLE 2. Kaplan-Meier Estimates for the Probability of No





















Follow-up is considered from the onset of prednisone therapy to the
first flare or the end of the study period.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(7.808 2.391 vs 6.709 2.436 g, P¼ 0.016), and the total
cumulative prednisone dose (15.545 8.868 vs
10.031 9.210 g, P¼ 0.0001) were significantly higher in
patients with flares.
Table 6 shows the prednisone dose and ESR and CRP
values at the time of relapse at different follow-up times. There
was a progressive reduction of the prednisone dose over time
(from 13.7 12.0 mg/day for the relapses occurring during the
first year of therapy to 2.3 1.3 mg/day for the relapses occur-
ring during the 5th year of treatment), whereas ESR and CRP
values remained stable over time.
Table 7 shows the laboratory characteristics and predni-
sone dose at each flare type.
CRP levels at the time of flare were lower in PMR flares
compared with the flares characterized by cranial manifes-
tations (P¼ 0.013). Prednisone dose at the time of flare was
significantly lower in PMR flares compared with the flares
characterized by cranial symptoms (P¼ 0.003) or systemic
manifestations (P< 0.0001), whereas flares presenting with
systemic manifestations were associated with higher prednisone
dose at the time of flare compared with those presenting with
loss of at least 4 kg, or fever.LVV (P¼ 0.038). Time from diagnosis to flare was longer in
flares characterized by PMR or LVV compared with those
characterized by cranial manifestations (P< 0.0001 and
www.md-journal.com | 5
TABLE 4. Main Characteristics at Time of First Relapse in 43




Polymyalgia rheumatic 20/43 (46.5)





Systemic manifestationsz 11/43 (25.6)
Acute-phase reactants
ESR, mm/h, meanSD 53 23
CRP, mg/dL, meanSD 4.4 3.0
Prednisone dose, mg/day
MeanSD 10.7 11.4
Median (IQR) 8.2 (2.8–12.5)
Time from diagnosis to relapses/recurrences, mo
MeanSD 14.5 11.8
Median (IQR) 12.0 (6.0–18.0)
CRP¼C-reactive protein, IQR¼ interquartile range.
Values are the number (%), except where otherwise indicated.
ESR¼ erythrocyte sedimentation rate.
Large vessel involvement: evidence of active large vessel vasculitis
at 18F-FDG positron emission tomography (FDG-PET).
yCranial symptoms: headache, scalp tenderness, jaw claudication,
temporal artery abnormalities, Carotidynia, cranial ischemic compli-
cations.
zPresence of at least one of the following: asthenia, anorexia, weight
loss of at least 4ckg, or fever.
TABLE 5. Main Characteristics and Timing of Relapses and Recu
Characteristic Relapses (n¼ 88)
Symptoms
Polymyalgia rheumatic 50/88 (56.8)





Systemic symptomsz 15/88 (17.0)
Acute-phase reactants
ESR, mm/h, meanSD 56 27
CRP, mg/dL, meanSD 4.0 3.0
Prednisone dose, mg/day
MeanSD 8.2 8.9
Median (IQR) 5 (2.5–10.0)
Time from diagnosis to flare, mo
MeanSD 32.1 32.0
Median (IQR) 20.5 (9–45)
Percentage of patients flaring per months of follow-up
0–12 mo 29/88 (33.0)
13–24 mo 19/88 (21.6)
25–36 mo 13/88 (14.8)
37–48 mo 9/88 (10.2)
49–60 mo 4/88 (4.5)
>60 mo 14/88 (15.9)
CRP¼C-reactive protein, ESR¼ erythrocyte sedimentation rate, IQR¼
Values are the number (%), except where otherwise indicated.
Large vessel involvement: evidence of active large vessel vasculitis a
yCranial symptoms: headache, scalp tenderness, jaw claudication, tempo
zPresence of at least one of the following: asthenia, anorexia, weight los
Restuccia et al
6 | www.md-journal.comP¼ 0.003, respectively) or systemic manifestations (P< 0.0002
and P¼ 0.005, respectively).
Time required to achieve a maintenance prednisone dose
<10 mg/day,<5 mg/day and time to treatment suspension were
compared between patients with and without flares using the
Kaplan-Meier survival analysis method (Figure 3).
Patients with flares required significantly longer periods of
time to reach a maintenance dose of prednisone <5 mg/day
(P¼ 0.014) (Figure 3B) and to completely suspend prednisone
therapy (P¼ 0.002) (Figure 3C).
Predictive Factors of Flare
Table 1 compares the demographic, clinical, laboratory,
histological findings, and comorbidities between patients with
and without flares.
At disease onset, fever  388C and systemic manifes-
tations were more frequently observed in flaring patients
(P¼ 0.022). No differences in the 2 groups were observed
for the considered comorbidities. Acute-phase reactants levels
at diagnosis were similar in patients with or without flare,
whereas hemoglobin levels were significantly lower in patients
with flares (P¼ 0.048). The TAB specimens of the patients with
flares had a significantly higher frequency of giant cells
(P¼ 0.038) and intraluminal acute thrombosis (P¼ 0.007)
and they were more inflamed compared with those of patients
without flares (P¼ 0.016). A moderate/severe inflammation in
temporal artery was present in 48 of 52 (92.3%) of patients with
Medicine  Volume 95, Number 19, May 2016flares and in 71 of 95 (74.7%) of patients without flares. The
difference was statistically significant (P¼ 0.009). A univariate
Cox proportional hazards model was used to assess the
rrences in 88 Relapses and 22 Recurrences
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TABLE 6. Prednisone Dose and ESR and CRP Levels at the
Time of Relapse at Different Follow-Up Times

Follow-up Time Prednisone Dose
0-12 mo
Prednisone, mg/day 13.7 12.0
ESR, mm/h 54 22
CRP, mg/dL 4.5 3.1
13-24 months
Prednisone, mg/day 7.6 6.2
ESR, mm/h 58 31
CRP, mg/dL 4.7 3.1
25-36 months
Prednisone, mg/day 5.8 4.1
ESR, mm/h 71 33
CRP, mg/dL 4.1 2.8
37-48 months
Prednisone, mg/day 3.4 3.1
ESR, mm/h 54 34
CRP, mg/dL 2.8 2.1
49-60 months
Prednisone, mg/day 2.3 1.3
ESR, mm/h 37 16
CRP, mg/dL 3.0 2.1
>60 months
Prednisone, mg/day 3.4 1.8
ESR, mm/h 49 14
CRP, mg/dL 2.9 3.4
Medicine  Volume 95, Number 19, May 2016association between increased risk of flare and findings at
diagnosis (Table 8).
The presence of fever (>388C) (HR 2.02, 95% CI 1.12–
3.65), giant cells (HR 2.58, 95% CI 1.10–6.04), intraluminal
acute thrombosis (HR 2.54, 95% CI 1.28–5.06), and the
severity of inflammatory infiltrate (moderate/severe vs mild)
CRP¼C-reactive protein, ESR¼ erythrocyte sedimentation rate.
Values are meanSD.(HR 3.47, 95% CI 1.25–9.65) were significantly associated
with an increased risk to develop flares, whereas low hemo-
globin levels (HR 0.77, 95% CI 0.62–0.96) were associated
TABLE 7. Laboratory Characteristics and Prednisone Dose at Eac
Polymyalgia
Rheumatica
ESR, mm/h 49 21
CRP, mg/dL 3.3 2.8
Prednisone dose at the time of flare, mg/day 4.2 2.6,y
Time from diagnosis to flare, mo 48.6 38.1§,jj
CRP¼C-reactive protein, ESR¼ erythrocyte sedimentation rate, ¼ larg
Values are MeanSD.
Versus cranial manifestations P¼ 0.013.
Versus cranial manifestations P¼ 0.003.
yVersus systemic manifestations P¼ 0.0001.
zVersus systemic manifestations P¼ 0.038.
§Versus cranial manifestations P< 0.0001.
jjVersus systemic manifestations P< 0.0001.
Versus cranial manifestations P¼ 0.003.
#Versus systemic manifestations P¼ 0.005.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.with a reduced risk to develop flares. In the multivariate model,
only fever  388C (HR 2.14, 95% CI 1.06–4.32) and the
severity of inflammatory infiltrate (moderate/severe vs mild)
(HR 5.41, 95% CI 1.64–17.87) were significantly associated
with increased risk of flare.
DISCUSSION
In our study, 36.5% of our patients followed for at least 4
years after the diagnosis of GCA had 1 flares. The frequency
of flares was overall similar to that reported by Martinez-Lado
et al,5 Kermani et al,11 and Liozon et al7 (40.8%, 34%, and
36.2%, respectively), but lower than that reported in 2 other
studies.6,8 Alba et al6 and Proven et al8 in their cohorts of
patients evaluated a frequency of flares of 64% and 48%,
respectively.
These differences are partially related to the different
definition of flare. We used a strict definition, considering flare
as reappearance of GCA-related clinical manifestations accom-
panied by elevated ESR and/or CRP that required treatment
adjustment. In a recent study from Mayo Clinic, the authors
found flares in 74.5% of patients with biopsy-proven GCA;
however, 28.6% of flares were related to increased serum
inflammatory markers only.9 When flares were identified by
the combination of symptoms and abnormal acute-phase reac-
tants, the frequency of flares dropped to 47.2%. In agreement
with other observational studies5,6,9 the more frequent clinical
manifestations at the time of flare were PMR, headache, and
systemic manifestations, whereas symptomatic large-vessel
involvement was rarely observed (only 3 patients). We also
confirmed previous observations that permanent visual loss is
usually observed at diagnosis and very rarely occurs as disease
flare after starting GC treatment.5,6,16
Our study also confirmed that flares may occur at any time
during the follow-up; however, they were more frequent during
the first 2 years (46.4%) after the diagnosis and subsequently
became less frequent except after 5 years when most exacer-
bations were recurrences.5,6 Most flares of GCA (78.2%)
occurred within the first 5 years from the diagnosis, as also
observed in other observational follow-up studies. Labarca
et al9 observed that 79% of first relapses occurred during the
Flares in GCAfirst 5 years, whereas in Alba et al’s study,6 92% of flares
occurred in the first 5 years of follow-up. In keeping with Alba







60 29 61 32 59 38
5.1 3.0 5.0 2.5 2.9 3.7
11.7 9.7 16.7 18.1 6.3 5.3z
16.7 13.5 15.9 14.9 53.2 42.1,#
e vessel vasculitis.
www.md-journal.com | 7
FIGURE 3. (A) Survival curve showing the time required to reach a maintenance prednisone dose <10 mg/day in patients with (broken
line) and without (solid line) flares. The median time in patients with flares was 30 weeks (95% confidence interval [CI]: 25.7–34.3 weeks),
whereas in patients without flares was 25.7 weeks (95% CI: 24.0–27.5 weeks) (P¼0.19). (B) Survival curve showing the time required to
reach a maintenance prednisone dose<5 mg/day in patients with (broken line) and without (solid line) flares. The median time in patients
with flares was 48 weeks (95% CI: 40.6–56.8 weeks), whereas in patients without flares was 38.9 weeks (95% CI: 33.7–44.0 weeks)
(P¼0.014). (C) Survival curve showing the time required to reach a stable dose of prednisone 0 mg/day in patients with (broken line) and
without (solid line) flares. The median time in patients with flares was 151.9 weeks (95% CI: 109.9–193.8 weeks), whereas in patients
.00
Restuccia et al Medicine  Volume 95, Number 19, May 2016occurred at lower prednisone doses, however, although ESR and
CRP values during relapses were lower compared with those
observed at disease onset, and the values of acute-phase reac-
tants at the time of relapse over time were stable. Similarly to
other studies,5,6 mean time to first relapse was 14.5 11.8
months with median 12 months (IQR, 6–18 months) and first
relapses occurred when patients were receiving a mean pre-
dnisone dose of 10.7 11.4 mg/day with a median dose of
without flares was 73.3 weeks (95% CI: 64.2–82.3 weeks) (P¼08.2 mg/day (IQR, 2.8–12.5 mg/day). Previous studies showed
that disease flares were rare on prednisone doses >20 mg/
day.5,6,11 Kermani et al11 observed that 54% of relapses
8 | www.md-journal.comoccurred on daily prednisone dose of 1 to 10 mg. In agreement
with these results, we observed that the majority of relapses
occurred with prednisone dosages  10 mg/day (82.9%),
whereas only 3 patients relapsed while receiving  25 mg/day.
We did not find differences in clinical manifestations and
acute-phase reactants between relapses and recurrences. We
observed that patients with recurrences had a significantly
longer time from diagnosis to flare because most of recurrences
2).occurred 5 years after the diagnosis, whereas most of relapses
occurred within the first year. As expected, we observed that
patients with relapses or recurrences had a longer duration of
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 8. Predictive Variables of Flares (Relapses or Recurrences)
Characteristic
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Fever >388C 2.02 (1.12–3.65) 0.019 2.14 (1.06–4.32) 0.03
Hemoglobin, g/dL 0.77 (0.62–0.96) 0.02 0.96 (0.76–1.21) 0.74
Giant cells 2.58 (1.10–6.04) 0.029 1.43 (0.56–3.65) 0.45
Intraluminal acute thrombosis 2.54 (1.28–5.06) 0.008 1.16 (0.49–2.77) 0.73
Severity of inflammation (moderate/severe vs mild) 3.47 (1.25–9.65) 0.017 5.41 (1.64–17.87) 0.006
Univariate and multivariate (backward stepwise approach) Cox proportional hazards models were used for analysis. 95% CI¼ 95% confidence
Medicine  Volume 95, Number 19, May 2016 Flares in GCAtherapy and a higher cumulative prednisone dose than those
who did not have GCA flares. We also evaluated the laboratory
characteristics and prednisone dose for each type of flare.
Confirming the observations of Alba et al,6 inflammation
markers were higher in flares characterized by systemic mani-
festations, particularly compared with those presenting with
PMR. However, we also observed that the prednisone dose at
the time of flare was lower in patients flaring with PMR or LVV
compared with those flaring with cranial manifestations or
systemic disease, whereas the time from diagnosis to flare
was longer. These findings indicate that PMR or LVV flares
occur later when disease activity progressively decreases and
lower prednisone doses are required to maintain remission.
Adrenal insufficiency causing PMR-like myalgia has been
reported after long-standing GC therapy in GCA, but unlike
true flares is not associated with elevated serum inflammatory
markers.19,20 Therefore, we emphasize the importance of a strict
definition of flares, particularly those characterized by PMR
manifestations, because in the absence of an increase in inflam-
matory markers, the distinction at low GC dosages between
symptoms of hypoadrenalism and mild disease activity, especi-
ally in retrospective studies, may be difficult.
A major issue in the treatment of patients with GCA is to
define predictors that at the time of GCA diagnosis may identify
patients at increased risk of flaring. As evidenced by other
authors,5,6 we observed that the mean duration of prednisone
treatment was longer and 1-year and total cumulative GC doses
were higher in patients with flares compared with those without
flares. Proven et al8 in a population-based study showed that
adverse events associated with GCs occurred in 86% of patients
and that a higher cumulative dose of GCs was associated with
the development of GC side effects.
Identification of reliable predictors of flares is an important
part of the research agenda of GCA because defining optimal
treatment strategies may shorten the treatment duration and
minimize the cumulative GC burden. Other studies have found
that a strong initial systemic inflammatory response and anemia
at diagnosis were associated with relapsing disease and pro-
longed GC therapy.5,6,10,12 In our study, systemic manifes-
tations, fever, and lower hemoglobin levels at diagnosis were
significantly more frequent in the patients with flares compared
with those without flares. No studies have evaluated the role of
pathological findings of TAB as predictors of future flares. We
observed that giant cells, intraluminal acute thrombosis, and
interval, HR¼ hazard ratio.severity of transmural inflammation were more frequent in
patients with flares. In the multivariate model, only fever
 388C and the severity of inflammation observed at TAB
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(moderate/severe vs mild) remained significantly associated
with an increased risk of flares. Our findings are consistent
with previous observations that a strong initial inflammatory
response is associated with a flaring disease course and pro-
longed requirements of GCs.5,6,10,12 Temporal artery biopsy
remains the criterion standard for the diagnosis of GCA;
however, our data showed that this procedure may also identify
patients at diagnosis with more severe disease. Further studies
need to confirm our observation.
Our study has several limitations. First, as in all retro-
spective studies, incomplete datasets may have influenced the
findings. Other limitation includes the possibility of referral
bias. Strength of the study was the long follow-up duration.
Furthermore, selecting only patients diagnosed and treated in
the Department of Rheumatology, patients included in the study
were uniformly evaluated and treated.
In conclusion, this study confirms that flares are frequent
in an Italian cohort of patients with biopsy-proven GCA. Fever
and severity of inflammation at TAB examination at diagnosis
predict the development of disease flares.
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